Skip to content

Daily vs Intermittent Restriction of Energy: Controlled Trial to Reduce Diabetes Risk (DIRECT)

Daily vs Intermittent Restriction of Energy: Randomised Controlled Trial to Reduce Diabetes Risk (DIRECT)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03689608
Enrollment
209
Registered
2018-09-28
Start date
2018-09-26
Completion date
2021-11-30
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Individuals at Risk of Developing Diabetes

Keywords

intermittent fasting, calorie restriction, overweight and obesity

Brief summary

In this randomized controlled trial, the investigators will compare the long term effectiveness of intermittent fasting (IF) versus an energy matched moderate calorie restriction (CR) over 18 months, and relative to a non-active intervention standard control (SC) in individuals who are at increased risk of developing type 2 diabetes. All participants will be required to attend the blood tests following a 12-hour overnight fast for the A visit at Month 0, 2, 6 (active) and 18 (follow up). Fast424hGlucose: A subset of 100 participants enrolled in either IF or CR group in the parent study will be fitted with a continuous glucose monitor (CGM) to measure 24-hour glycaemic profile at month 0 and month 6. Fast4Switch: Additional bloods will be collected after a B visit at month 6 to compare the fed to fasted switch. The B samples will be collected after a 12-hour overnight fast (CR, SC) or 20-hour fast (IF) to assess the metabolic switch to fasting in metabolites and hormones. Fast4Stress: Additional subcutaneous adipose tissue, urine and saliva samples will be collected in \ 32 men in IF and CR groups at month 0 and 6 at A and B visits to examine changes in stress response and resistance markers. Experience2Fast: In-depth, semi-structured interviews will be carried out at month-8 follow-up visit in a subset of completers from IF or CR groups to explore the experience of intervention diets and understand contributing factors towards change and maintenance of dietary behaviours. Fast4Flux: Additional blood samples will be collected in \ 100 individuals in SC, IF and CR groups at month 0, month 2 and month 6 at A visit to measure autophagic flux in peripheral blood mononuclear cells following treatment of whole blood.

Interventions

Participants will fast 3 days per week. In fasting days, meal replacements at 30% of daily energy requirements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.

OTHERDaily Restriction (DR)

Participants are instructed to restrict energy intake by 30% of daily energy requirements. Meal replacements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.

Participants will receive current practice guidelines in a static information format, will not take part in any counselling or receive meal replacements.

Sponsors

University of Adelaide
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* weight-stable (\< 5 % fluctuation in their body weight for past 6-months at study entry) * score 12 or greater on the AUSDRISK calculator * HbA1c \<48 mmol/mol (measured at screening)

Exclusion criteria

* Personal history/diagnosis (self-reported) of diabetes (type 1 or 2), major psychiatric disorders (schizophrenia, major depressive disorder, bipolar disorder, eating disorders), gastrointestinal disorders, haematological disorders (i.e. thalassemia, iron-deficiency anaemia) insomnia, or any other medical condition, deemed unstable by the study physician. * Participants currently taking the following medications will be excluded from participating: any medication used to lower blood glucose or antidiabetic medications (metformin, sulfonylureas, Glucagon-like peptide-1 GLP-1 analogues \[i.e. exenatide\], thiazolidinediones or DPP-IV inhibitors \[i.e. 'gliptins'\]), medications affecting weight, appetite or gut motility (i.e. domperidone, cisapride, orlistat, phentermine, topiramate). Participants who are taking stable doses (i.e. \> 12 months) of androgenic medications (i.e. testosterone) or SSRI's will not be excluded. * weight change in past 3 months (\> 5% screening weight) * uncontrolled asthma, current fever, upper respiratory infections * individuals who regularly perform high intensity exercise (\>2 week) * current intake of \> 140g alcohol/week * current smokers of cigarettes/cigars/marijuana/e-cigarettes/vaporisers * current intake of any recreational drugs * regular blood donor * unable to comprehend study protocol due to English language or cognitive difficulties

Design outcomes

Primary

MeasureTime frameDescription
Postprandial glucose AUC6 monthsChange in postprandial glucose AUC

Secondary

MeasureTime frameDescription
HbA1c2 months, 6 months, 18 monthsChange in HbA1c
Postprandial glucose18 monthsChange in postprandial glucose
Body weight2 months, 6 months, 18 monthsChange in body weight in kilograms
Body composition6 months, 18 monthsChange in body fat mass (kg) and fat free mass (kg)
Waist and hip circumference2 months, 6 months, 18 monthsChange in waist and hip circumference
Blood lipids2 months, 6 months, 18 monthsChanges in blood lipid profile (total cholesterol, HDL-, LDL-cholesterol and triglycerides)
Dietary intake2 months, 6 months, 18 monthsChange in food intake measured by self-reported food diaries
Postprandial triglyceride6 months, 18 monthsChange in postprandial triglyceride levels
Changes in physical Activity assessed by accelerometer2 months, 6 months, 18 monthsChange in average step counts measured with waist-worn actigraphy monitors
Fasting glucose2 months, 6 months, 18 monthsChange in fasting glucose
Fasting insulin2 months, 6 months, 18 monthsChange in fasting insulin
Fasting non-esterified fatty acids (NEFA)2 months, 6 months, 18 monthsChange in fasting NEFA levels
Fasting triglyceride2 months, 6 months, 18 monthsChange in fasting triglyceride levels
Postprandial insulin6 months, 18 monthsChange in postprandial insulin
Postprandial non-esterified fatty acids (NEFA)6 months, 18 monthsChange in postprandial NEFA levels
Blood pressure2 months, 6 months, 18 monthsChange in systolic blood pressure and diastolic blood pressure (mmHg)

Other

MeasureTime frameDescription
Change in insulin (DIRECT- Fast4Switch)6 monthsChange in insulin levels
Change in triglycerides (DIRECT- Fast4Switch)6 monthsChange in triglycerides levels
24 hours glycaemia (DIRECT-Fast424hGlucose)6 monthsChanges in 24 hours glycaemia assessed by continuous glucose monitor
Salivary cortisol (DIRECT-Fast4Stress)6 monthsChange in salivary cortisol
Change in perceived hunger and fullness assessed by visual analogue scales (VAS)6 months, 18 monthsChange in subjective hunger and fullness ratings measured by 0-100 mm VAS scales
Change in urinary adrenaline (DIRECT- Fast4Stress)6 monthsChange in urinary adrenaline
Change in urinary noradrenaline (DIRECT- Fast4Stress)6 monthsChange in urinary noradrenaline
Qualitative analysis (DIRECT-Experience2Fast)8 monthsPatterns of participant's behaviour, characteristics and motivation that assist in or hinder from weight loss achievement by semi-structured interviews
Change in autophagic flux (DIRECT-Fast4flux)2 months, 6 monthsChange in autophagic machinery protein LC3B-II in peripheral blood mononuclear cells following treatment of whole blood.
Gene expression (DIRECT- Fast4Stress)6 monthsChange in gene expression
Change in perceived sleep quality2 months, 6 months, 18 monthsChange in perceived sleep quality assessed by Pittsburgh Sleep Quality Index (PSQI), with a range from 0-21 scores, higher score reflect poorer sleep quality
Change in perceived eating behaviour2 months, 6 months, 18 monthsChange in perceived eating behaviour assessed by Three Factor Eating Questionnaire (TFEQ), which consists of 51 items to assess dietary restraint (21 items), disinhibition (16 items) and hunger (14 items), higher scores reflect higher levels on each subscale
Change in perceived quality of life2 months, 6 months, 18 monthsChange in perceived quality of life assessed by 36-item Short Form (SF-36) health survey, with a range from 0-100 scores, higher scores reflect better quality of life
Change in perceived well-being2 months, 6 months, 18 monthsChange in perceived well-being assessed by Personal Well-being Index, with a range from 0-10 scores, higher scores reflect greater satisfication
Change in food addition score6 months, 18 monthsChange in self-reported food addiction assessed by Yale Food Addiction Score (YFAS), with a range from 0-7 scores, higher scores reflect greater food addiction symptoms
Change in psychological distress6 months, 18 monthsChange in self-reported psychological distress assessed by Kessler Psychological Distress Scale (K10) , with a range from 10-50 scores, higher scores reflect higher psychological distress
Change in self-reported depression, anxiety and stress level2 months, 6 months, 18 monthsChange in self-reported depression, anxiety and stress level assessed by Depression, Anxiety and Stress Scale (DASS), with a range from 0-42 scores on each subscale, higher scores reflect higher levels on each subscale
Change in self-reported mood2 months, 6 months, 18 monthsChange in self-reported mood assessed by Positive and Negative Affect Schedule (PANAS), with a range from 0-100 scores, higher scores reflect more positive mood and negative mood.
Change in glucagon-like peptide 1 (GLP-1)6 monthsChange in glucagon-like peptide 1 (GLP-1)
Change in peptide YY6 monthsChange in peptide YY
Change in ghrelin6 monthsChange in ghrelin
Change in gastric inhibitory polypeptide (GIP)6 monthsChange in gastric inhibitory polypeptide (GIP)
Change in estradiol6 monthsChange in estradiol
Change in testosterone6 monthsChange in testosterone
Change in glucose (DIRECT- Fast4Switch)6 monthsChange in glucose levels
Change in non-esterified fatty acids (DIRECT- Fast4Switch)6 monthsChange in non-esterified fatty acids levels (NEFA)

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026